ISTA Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
ISTA Pharmaceuticals, Inc.
Industry Pharmaceuticals
Founded 1992
Headquarters Irvine, California
Key people

Vicente Anido Jr., Ph.D., President, Chief Executive Officer, Glenn E. Davis, Vice President, Chief Compliance Officer, Marvin J. Garrett, Vice President, Regulatory Affairs, Quality & Compliance, Kathleen McGinley, Vice President, Human Resources & Corporate Services, Kirk McMullin, Vice President, Operations Timothy R. McNamara, PharmD, Vice President, Clinical Research & Medical Affairs

Tom Mitro, Vice President, Sales & Marketing
Products Bromday, Bepreve, Xibrom, Istalol, Vitrase

ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specializes in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.[1] ISTA was acquired by Bausch & Lomb on March 26, 2012.[2]

In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.[3]


  • Bromday (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction[4]
  • Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of itching associated with signs and symptoms of allergic conjunctivitis[5]
  • Xibrom (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery (no longer being manufactured as of February 2011)
  • Istalol (timolol maleate ophthalmic solution) 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma[6]
  • Vitrase (hyaluronidase injection) Ovine, 200 USP Units/mL for use as an adjuvant to increase the absorption and ispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents[7]


On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.[8]


External links[edit]